AI drug design
AI drug design
[ ABOUT US
METANOVA LABS is building the future of drug development. Through NOVA, our decentralized discovery platform, we coordinate machine learning competitions, agents, and human intelligence to discover novel therapeutics and continuously improve the tools to find them. Our R&D focuses on next-generation therapies that regulate mental states and restore critical biological processes. We are building AI systems not just to accelerate our own R&D but to empower medical innovation by all.
METANOVA LABS is building the future of drug development. Through NOVA, our decentralized discovery platform, we coordinate machine learning competitions, agents, and human intelligence to discover novel therapeutics and continuously improve the tools to find them. Our R&D focuses on next-generation therapies that regulate mental states and restore critical biological processes. We are building AI systems not just to accelerate our own R&D but to empower medical innovation by all.
Reprogramming
body + mind
Drug Possiblities
finding new solutions
30 / 3.230 Targets
We transcend disease‑centric medicine by focusing on the neurosignaling circuits that shape thought, emotion, and behavior. We’re on a mission to develop innovative small molecules that target systems associated with reward and learning mechanisms key in regulating focus, appetite, social connection, rest, sleep, and other foundational behaviors for lifelong health and wellbeing. Our meta‑programming drugs operate at the source to foster lasting change. Our mission is to rewrite the rules of drug discovery by:
unlocking a deeper, more intelligent approach to healing and human potential
Traditional drug development is slow, expensive, and often siloed. We believe the future of medicine lies in open, incentive‑driven competition, where breakthroughs happen faster and cheaper. Our goal isn’t just to treat symptoms—it’s to optimize the underlying biological networks that define our health.
Reprogramming
body + mind
Drug Possiblities
finding new solutions
30 / 3.230 Targets
We transcend disease‑centric medicine by focusing on the neurosignaling circuits that shape thought, emotion, and behavior. We’re on a mission to develop innovative small molecules that target systems associated with reward and learning mechanisms key in regulating focus, appetite, social connection, rest, sleep, and other foundational behaviors for lifelong health and wellbeing. Our meta‑programming drugs operate at the source to foster lasting change. Our mission is to rewrite the rules of drug discovery by:
unlocking a deeper, more intelligent approach to healing and human potential
Traditional drug development is slow, expensive, and often siloed. We believe the future of medicine lies in open, incentive‑driven competition, where breakthroughs happen faster and cheaper. Our goal isn’t just to treat symptoms—it’s to optimize the underlying biological networks that define our health.
Reprogramming
body + mind
Drug Possiblities
finding new solutions
30 / 3.230 Targets
We transcend disease‑centric medicine by focusing on the neurosignaling circuits that shape thought, emotion, and behavior. We’re on a mission to develop innovative small molecules that target systems associated with reward and learning mechanisms key in regulating focus, appetite, social connection, rest, sleep, and other foundational behaviors for lifelong health and wellbeing. Our meta‑programming drugs operate at the source to foster lasting change. Our mission is to rewrite the rules of drug discovery by:
unlocking a deeper, more intelligent approach to healing and human potential
Traditional drug development is slow, expensive, and often siloed. We believe the future of medicine lies in open, incentive‑driven competition, where breakthroughs happen faster and cheaper. Our goal isn’t just to treat symptoms—it’s to optimize the underlying biological networks that define our health.
Decentralized
merit-based competition
is necessary to deliver
the promise of ai
PROCESSING SUBMISSIONS
EVALUATING SUBMISSIONS
102.932 / 3.232.943.203 Molecules
Centralized AI drug discovery platforms reward secrecy over scientific progress—models and data are locked behind NDAs to protect valuations, teams duplicate each other’s efforts, and exploration is confined to well‑trodden chemical scaffolds. This siloed approach breeds redundancy, stifles collaboration, and makes it very difficult to scale to truly novel regions of the chemical universe. Without open data‑sharing or adversarial stress‑testing, AI models overfit to narrow datasets and falter when faced with unprecedented targets.
NOVA flips the script. By harnessing a decentralized, token incentivized system, we align rewards with transparency and merit. Participants compete to submit high‑affinity molecules and nanobodies across tens of billions of possibilities. In addition, our algorithmic competitions allow us to open source and push the boundary of search approaches.
Decentralized
merit-based competition
is necessary to deliver
the promise of ai
PROCESSING SUBMISSIONS
EVALUATING SUBMISSIONS
102.932 / 3.232.943.203 Molecules
Centralized AI drug discovery platforms reward secrecy over scientific progress—models and data are locked behind NDAs to protect valuations, teams duplicate each other’s efforts, and exploration is confined to well‑trodden chemical scaffolds. This siloed approach breeds redundancy, stifles collaboration, and makes it very difficult to scale to truly novel regions of the chemical universe. Without open data‑sharing or adversarial stress‑testing, AI models overfit to narrow datasets and falter when faced with unprecedented targets.
NOVA flips the script. By harnessing a decentralized, token incentivized system, we align rewards with transparency and merit. Participants compete to submit high‑affinity molecules and nanobodies across tens of billions of possibilities. In addition, our algorithmic competitions allow us to open source and push the boundary of search approaches.
Decentralized
merit-based competition is
necessary to deliver
the promise of ai
PROCESSING SUBMISSIONS
EVALUATING SUBMISSIONS
102.932 / 3.232.943.203 Molecules
Centralized AI drug discovery platforms reward secrecy over scientific progress—models and data are locked behind NDAs to protect valuations, teams duplicate each other’s efforts, and exploration is confined to well‑trodden chemical scaffolds. This siloed approach breeds redundancy, stifles collaboration, and makes it very difficult to scale to truly novel regions of the chemical universe. Without open data‑sharing or adversarial stress‑testing, AI models overfit to narrow datasets and falter when faced with unprecedented targets.
NOVA flips the script. By harnessing a decentralized, token incentivized system, we align rewards with transparency and merit. Participants compete to submit high‑affinity molecules and nanobodies across tens of billions of possibilities. In addition, our algorithmic competitions allow us to open source and push the boundary of search approaches.
Introducing
Introducing
NOVA
NOVA
NOVA // CURRENT STATUS
SEARCHING
102.932
/
3.232.943.203
Molecules
Global,
decentralized
engine for
drug discovery
accelerating medical innovation
with the power of global market-driven competition
Virtual drug
Screening at
Lightning speed
NOVA pushes virtual drug screening beyond state-of-the-art models and transforms it into a high‑speed race for breakthroughs that rewards experts and enthusiasts alike. To win, find the best solution the fastest.
Virtual drug
Screening at
Lightning speed
NOVA pushes virtual drug screening beyond state-of-the-art models and transforms it into a high‑speed race for breakthroughs that rewards experts and enthusiasts alike. To win, find the best solution the fastest.
Virtual drug
Screening at
Lightning speed
NOVA pushes virtual drug screening beyond state-of-the-art models and transforms it into a high‑speed race for breakthroughs that rewards experts and enthusiasts alike. To win, find the best solution the fastest.
